Overview
- The companies' boards approved the deal on Monday, July 20, 2026, valuing Personalis at $1.5 billion or $16.25 per share and structuring consideration as stock with an option to pay up to 50% in cash and a maximum exchange ratio of 0.3356.
- Tempus says it will integrate Personalis' tumor-informed NeXT Personal minimal residual disease (MRD) assay and genomic datasets into its AI-driven precision oncology tools and expects the transaction to close in late 2026 or early 2027 after shareholder and regulatory reviews.
- Personalis reported preliminary second-quarter revenue of $22.4 million and delivered 10,384 clinical MRD tests in the quarter, a 33% increase in test volumes from the prior quarter, which the companies cite as evidence of growing commercial momentum and reimbursement traction.
- Markets reacted negatively to the deal announcement, with Tempus and Personalis shares each falling roughly 9% on the day, and analysts pointed to mixed sentiment, concerns over Personalis' loss-making status, and recent insider sales at Tempus as sources of investor unease.
- The purchase magnifies questions about the value and control of proprietary tumor and genomic data, the role of Medicare coverage in scaling MRD testing, and whether the combined company can accelerate adoption of recurrence monitoring that could change how patients are followed after cancer treatment.